project id: TCGA-BLCA; case submitter id: TCGA-UY-A78K; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.84; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.85; rna integrity number: 9.2; age at index: 60; days to birth: -22020; days to death: 536; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Dead; age at diagnosis: 22020; ajcc clinical t: T2; ajcc pathologic m: MX; ajcc pathologic n: N2; ajcc pathologic stage: Stage IV; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8130/3; primary diagnosis: Papillary transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to sample procurement: 0; initial weight: 160.0; portion submitter id: TCGA-UY-A78K-01A-11; percent lymphocyte infiltration: 5.0; percent monocyte infiltration: 1.0; percent necrosis: 1.0; percent neutrophil infiltration: 4.0; percent normal cells: 0.0; percent stromal cells: 29.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0;